NLS Pharmaceutics AG (NLSP)

USD 1.58

(5.33%)

Market Cap (In USD)

3.9 Million

Revenue (In USD)

-

Net Income (In USD)

-12.17 Million

Avg. Volume

930.72 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
1.73-24.32
PE
-0.23
EPS
-6.74
Beta Value
-0.522
ISIN
CH0523961370
CUSIP
H57830103
CIK
1783036
Shares
2472440.0
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Alexander Zwyer M.B.A.
Employee Count
-
Website
https://nlspharma.com
Ipo Date
2021-01-29
Details
NLS Pharmaceutics AG, a biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience to treat excessive daytime sleepiness and cataplexy; and Nolazol for the treatment of ADHD. The company was incorporated in 2015 and is based in Zurich, Switzerland.